| Name | Title | Contact Details |
|---|
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
Quartesian delivers quality, expertise, and speed so you can master your data to take control of your clinical trial.
Y's Therapeutics, Inc is a San Bruno, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fusion MD Network is a Montreal, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Altegra Health is a national provider of technology-enabled, end-to-end payment solutions that enable health plans and other risk-bearing organizations to generate, analyze and submit the data needed to successfully manage member care and ensure appropriate reimbursement. The power of Altegra Health’s advanced analytics and supporting interventions enables healthcare organizations to elevate care quality, optimize financial performance, and enhance the member experience.